Search for useful tools: Biomarkers in lupus nephritis

Future Rheumatology

Volumn 3, Issue 1, 2008, Pages 1-6

  Lee, Iris J ^a   Madaio, Michael P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD27 ANTIGEN; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4D; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 6; LA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SM ANTIBODY; STEROID;

DISEASE ACTIVITY; DISEASE SEVERITY; EARLY DIAGNOSIS; EDITORIAL; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINURIA; PROTEOMICS; REGULATORY T LYMPHOCYTE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 40749148078     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.1.1     Document Type: Editorial

References (47)

1. Houssiau FA, Vasconcelos C, D'Cruz D et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121-2131 (2002).
2. Illei GG, Takada K, Parkin D et al.: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46, 995-1002 (2002).
3. Zimmerman R, Radhakrishnan J, Valeri A. Appel G: Advances in the treatment of lupus nephritis. Annu. Rev. Med. 52, 63-78 (2001).
4. Reveille JD: Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 13, 290-297 (2004).
5. Hill GS. Delahousse M, Nochy D et al.: A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int. 58, 1160-1173 (2000).
6. Illei GG, Tackey E, Lapteva L, Lipsky PE: Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 50, 2048-2065 (2004).
7. Hartung K, Baur MP, Coldewey R et al.: Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J. Clin. Invest. 90, 1346-1351 (1992).
8. Liu CC, Manzi S, Danchenko N, Ahearn JM: New advances in measurement of complement activation: lessons of systemic lupus erythematosus. Curr. Rheumatol. Rep. 6, 375-381 (2004).
9. Liu CC, Manzi S, Ahearn JM: Biomarkers for systemic lupus erythematosus: a review and perspective. Curr. Opin. Rheumatol. 17, 543-549 (2005).
10. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP: Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J. Immunol. 166, 3915-3922 (2001).
11. Linker-Israeli M, Wallace DJ, Prehn J et al.: Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun. 1, 45-52 (1999).
12. Wilson AG, Gordon C, di Giovine FS et al.: A genetic association between systemic lupus erythematosus and tumor necrosis factor α. Eur J. Immunol. 24, 191-195 (1994).
13. Lee JY, Goldman D, Piliero LM, Petri M, Sullivan KE: Interferon-γ polymorphisms in systemic lupus erythematosus. Genes Immun. 2, 254-257 (2001).
14. Matsushita M, Tsuchiya N, Oka T, Yamane A, Tokunaga K: New polymorphisms of human CD80 and CD86. lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun. 1, 428-434 (2000).
15. Prokunina L, Castillejo-Lopez C, Oberg F et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666-669 (2002).
16. Kojima T, Hodriuchi T, Nishizaki H et al.: Analysis of fas ligand gene mutation in patients with systemic lupus erythematosus. Arthritis Rheum. 43, 135-139 (2000).
17. Kanemitsu S, Ihara K, Saifddin A et al.: A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 29, 1183-1188 (2002).
18. Wu H, Shen N, Gu Y et al.: [Association between Bcl-2 gene polymorphism with systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi 82, 467-470 (2002).
19. Karassa FB. Trikalinos TA, Ioannidis JP: Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 46, 1563-1571 (2002).
20. Karassa FB, Trikalinos TA, Ioannidis JP: The Fcγ RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int. 63, 1475-1482 (2003).
21. Crow MK, Kirou KA, Wohlgemuth J: Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36, 481-490 (2003).
22. Bennett L, Palucka AK, Arce E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
23. Baechler EC, Gregersen PK, Behrens TW: The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807 (2004).
24. Peterson KS, Huang JF, Zhu J et al.: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113, 1722-1733 (2004).
25. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).
26. Korbet SM, Lewis FJ, Schwartz MM, Reichlin M, Evans J, Rohde RD: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am. J. Kidney Dis. 35, 904-914 (2000).
27. Manzi S, Navratil JS, Ruffing MJ et al.: Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 50, 3596-3604 (2004).
28. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J: Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxford) 43, 220-224 (2004).
29. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177, 1367-1381 (1993).
30. Min DJ, Kim SK, Park SH et al.: Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin. Exp. Rheumatol. 20, 13-18 (2002).
31. Horvath L, Czirjak L, Fekete B et al.: High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol. 19, 667-672 (2001).
32. Moroni G, Trendelenburg M, del Papa N et al.: Anti-Clq antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis. 37, 490-498 (2001).
33. high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13, 283-289 (2004).
34. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al.: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8, R83 (2006).
35. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123, 66-73 (2007).
36. Kyttaris VC, Juang YT, Tsokos GC: Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 17, 518-522 (2005).
37. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am. Soc. Nephrol. 11, 152-176 (2000).
38. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147, 117-123 (1991).
39. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH: Elevated interieukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 16, 283-288 (1998).
40. Li Y, Tucci M, Narain S et al.: Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 5, 383-388 (2006).
41. Narumi S, Takeuchi T, Kobayashi Y, Konishi K: Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12, 1561-1565 (2000).
42. Avihingsanon Y, Phumesin P, Benjachat T et al.: Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int. 69, 747-753 (2006).
43. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467-473 (2005).
44. Campbell S, Burkly LC, Can HX et al.: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J. Immunol. 176, 1889-1898 (2006).
45. Schwartz N, Michaelson JS, Putterman C: Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann. NY Acad. Sci. 1109, 265-274 (2007).
46. Schaub S, Rush D, Wilkins J et al.: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 15, 219-227 (2004).
47. Mosley K, Tam FW, Edwards PJ, Crozier J, Pusey CD, Lightstone L: Urinary proteomic profiles distinguish between active and Inactive lupus nephritis. Rheumatology (Oxford) 45, 1497-1504 (2006).